[6-K] Haleon plc American Current Report (Foreign Issuer)
Haleon plc (LSE/NYSE: HLN) disclosed a notification under the UK Market Abuse Regulation for a transaction by a Person Discharging Managerial Responsibilities (PDMR). The Company received the notice on 10 September 2025 and reported an executed trade of 34 matching shares at a price of £3.6182 per share. The filing is a routine regulatory disclosure of insider dealing activity and includes the Company’s principal office address in Weybridge, Surrey.
The document also lists Haleon’s consumer brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, and directs readers to www.haleon.com for more information. The filing contains transaction detail limited to volume and price; other typical fields are present in template form but not populated with additional substantive data.
Haleon plc (LSE/NYSE: HLN) ha comunicato, ai sensi del UK Market Abuse Regulation, una notifica relativa a una transazione effettuata da una Persona con Responsabilità Dirigenziali (PDMR). La Società ha ricevuto l’avviso il 10 September 2025 e ha riportato l’esecuzione di un’operazione su 34 azioni corrispondenti al prezzo di £3.6182 per azione. La segnalazione è una divulgazione regolamentare di routine sull’attività di insider dealing e include l’indirizzo della sede principale dell’azienda a Weybridge, Surrey.
Il documento elenca inoltre i marchi consumer di Haleon come Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu e Voltaren e rimanda a www.haleon.com per ulteriori informazioni. La comunicazione contiene i dettagli della transazione limitati a volume e prezzo; altri campi tipici del modello sono presenti ma non compilati con ulteriori dati sostanziali.
Haleon plc (LSE/NYSE: HLN) notificó, conforme al UK Market Abuse Regulation, una transacción realizada por una Persona con Responsabilidades de Dirección (PDMR). La Compañía recibió el aviso el 10 September 2025 y registró una operación ejecutada de 34 acciones coincidentes a un precio de £3.6182 por acción. La presentación es una divulgación regulatoria rutinaria sobre actividad de insider dealing e incluye la dirección de la oficina principal en Weybridge, Surrey.
El documento también enumera las marcas de consumo de Haleon como Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu y Voltaren, y remite a www.haleon.com para más información. La notificación contiene detalles de la transacción limitados a volumen y precio; otros campos habituales del formulario aparecen, pero no se han completado con datos sustantivos adicionales.
Haleon plc (LSE/NYSE: HLN)는 UK Market Abuse Regulation에 따른 임원 의무자(PDMR)의 거래 통지를 공시했습니다. 회사는 해당 통지를 10 September 2025에 접수했으며, 주당 £3.6182에 34주 매칭 거래가 체결되었음을 보고했습니다. 해당 제출서는 내부자 거래 활동에 대한 일상적인 규제 공시이며 본사의 주소(영국 Surrey, Weybridge)를 포함하고 있습니다.
문서에는 또한 Haleon의 소비자 브랜드로 Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu 및 Voltaren이 기재되어 있으며 자세한 정보는 www.haleon.com을 참조하라고 안내합니다. 제출서에는 거래 세부정보가 수량과 가격으로 제한되어 있으며, 양식의 다른 일반 항목들은 있으나 추가 실질 데이터는 기재되지 않았습니다.
Haleon plc (LSE/NYSE: HLN) a communiqué, en vertu du UK Market Abuse Regulation, une notification concernant une transaction réalisée par une Personne exerçant des responsabilités managériales (PDMR). La Société a reçu l’avis le 10 September 2025 et a déclaré une opération exécutée de 34 actions correspondantes au prix de £3.6182 par action. Le dépôt constitue une divulgation réglementaire de routine d’activité d’initié et inclut l’adresse du siège social à Weybridge, Surrey.
Le document énumère également les marques grand public de Haleon telles que Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu et Voltaren, et renvoie à www.haleon.com pour plus d’informations. La notification contient des détails de la transaction limités au volume et au prix ; d’autres champs habituels du modèle figurent mais ne sont pas renseignés avec des données substantielles supplémentaires.
Haleon plc (LSE/NYSE: HLN) hat gemäß der UK Market Abuse Regulation eine Meldung über eine Transaktion einer Person mit Führungsverantwortung (PDMR) offengelegt. Das Unternehmen erhielt die Mitteilung am 10 September 2025 und meldete einen ausgeführten Handel über 34 übereinstimmende Aktien zum Preis von £3.6182 je Aktie. Die Einreichung ist eine routinemäßige regulatorische Offenlegung von Insider-Handelsaktivitäten und enthält die Anschrift des Hauptsitzes in Weybridge, Surrey.
Das Dokument nennt außerdem Haleons Verbraucher-Marken wie Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu und Voltaren und verweist für weitere Informationen auf www.haleon.com. Die Meldung enthält Transaktionsdetails, die auf Volumen und Preis beschränkt sind; andere typische Felder der Vorlage sind zwar vorhanden, aber nicht mit zusätzlichen substanziellen Angaben ausgefüllt.
- Regulatory compliance: Company disclosed a PDMR transaction in accordance with the UK Market Abuse Regulation.
- Transaction detail provided: The filing specifies the exact volume (34 matching shares) and price (£3.6182), enabling market transparency.
- None.
Insights
TL;DR: Routine insider transaction disclosure; meets UK MAR/PDMR reporting requirements with basic volume and price detail.
The filing is a standard Form 6-K notice describing a PDMR transaction received on 10 September 2025. It provides the essential details required for market transparency: the number of matching shares traded (34) and the trade price (£3.6182). From a governance perspective, timely disclosure of insider trading maintains regulatory compliance and investor transparency. The filing contains limited additional information and appears mechanistic rather than signaling any corporate governance change.
TL;DR: Minor insider share transaction disclosed; immaterial to company fundamentals given small volume reported.
The reported transaction—34 matching shares at £3.6182—represents a very small nominal value trade relative to a public company and thus is unlikely to be material to investors or affect market valuation. The report complies with disclosure norms but lacks context such as aggregate holdings before/after the trade or the PDMR identity. No earnings, debt, or operational metrics are provided, so there is no direct impact on financial analysis from this filing alone.
Haleon plc (LSE/NYSE: HLN) ha comunicato, ai sensi del UK Market Abuse Regulation, una notifica relativa a una transazione effettuata da una Persona con Responsabilità Dirigenziali (PDMR). La Società ha ricevuto l’avviso il 10 September 2025 e ha riportato l’esecuzione di un’operazione su 34 azioni corrispondenti al prezzo di £3.6182 per azione. La segnalazione è una divulgazione regolamentare di routine sull’attività di insider dealing e include l’indirizzo della sede principale dell’azienda a Weybridge, Surrey.
Il documento elenca inoltre i marchi consumer di Haleon come Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu e Voltaren e rimanda a www.haleon.com per ulteriori informazioni. La comunicazione contiene i dettagli della transazione limitati a volume e prezzo; altri campi tipici del modello sono presenti ma non compilati con ulteriori dati sostanziali.
Haleon plc (LSE/NYSE: HLN) notificó, conforme al UK Market Abuse Regulation, una transacción realizada por una Persona con Responsabilidades de Dirección (PDMR). La Compañía recibió el aviso el 10 September 2025 y registró una operación ejecutada de 34 acciones coincidentes a un precio de £3.6182 por acción. La presentación es una divulgación regulatoria rutinaria sobre actividad de insider dealing e incluye la dirección de la oficina principal en Weybridge, Surrey.
El documento también enumera las marcas de consumo de Haleon como Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu y Voltaren, y remite a www.haleon.com para más información. La notificación contiene detalles de la transacción limitados a volumen y precio; otros campos habituales del formulario aparecen, pero no se han completado con datos sustantivos adicionales.
Haleon plc (LSE/NYSE: HLN)는 UK Market Abuse Regulation에 따른 임원 의무자(PDMR)의 거래 통지를 공시했습니다. 회사는 해당 통지를 10 September 2025에 접수했으며, 주당 £3.6182에 34주 매칭 거래가 체결되었음을 보고했습니다. 해당 제출서는 내부자 거래 활동에 대한 일상적인 규제 공시이며 본사의 주소(영국 Surrey, Weybridge)를 포함하고 있습니다.
문서에는 또한 Haleon의 소비자 브랜드로 Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu 및 Voltaren이 기재되어 있으며 자세한 정보는 www.haleon.com을 참조하라고 안내합니다. 제출서에는 거래 세부정보가 수량과 가격으로 제한되어 있으며, 양식의 다른 일반 항목들은 있으나 추가 실질 데이터는 기재되지 않았습니다.
Haleon plc (LSE/NYSE: HLN) a communiqué, en vertu du UK Market Abuse Regulation, une notification concernant une transaction réalisée par une Personne exerçant des responsabilités managériales (PDMR). La Société a reçu l’avis le 10 September 2025 et a déclaré une opération exécutée de 34 actions correspondantes au prix de £3.6182 par action. Le dépôt constitue une divulgation réglementaire de routine d’activité d’initié et inclut l’adresse du siège social à Weybridge, Surrey.
Le document énumère également les marques grand public de Haleon telles que Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu et Voltaren, et renvoie à www.haleon.com pour plus d’informations. La notification contient des détails de la transaction limités au volume et au prix ; d’autres champs habituels du modèle figurent mais ne sont pas renseignés avec des données substantielles supplémentaires.
Haleon plc (LSE/NYSE: HLN) hat gemäß der UK Market Abuse Regulation eine Meldung über eine Transaktion einer Person mit Führungsverantwortung (PDMR) offengelegt. Das Unternehmen erhielt die Mitteilung am 10 September 2025 und meldete einen ausgeführten Handel über 34 übereinstimmende Aktien zum Preis von £3.6182 je Aktie. Die Einreichung ist eine routinemäßige regulatorische Offenlegung von Insider-Handelsaktivitäten und enthält die Anschrift des Hauptsitzes in Weybridge, Surrey.
Das Dokument nennt außerdem Haleons Verbraucher-Marken wie Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu und Voltaren und verweist für weitere Informationen auf www.haleon.com. Die Meldung enthält Transaktionsdetails, die auf Volumen und Preis beschränkt sind; andere typische Felder der Vorlage sind zwar vorhanden, aber nicht mit zusätzlichen substanziellen Angaben ausgefüllt.
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
|
Exhibit
Number
|
Description
|
|
99.1
|
10
September 2025 - “Director/PDMR
Shareholding”
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Adrian Morris
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
General Counsel - PDMR
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification code
|
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares
under the Company's Share Reward Plan
|
|||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.6182
|
34
|
|
|
|
|
|
£Nil
|
34 (Matching Shares)
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
|
|
||||
|
- Aggregated volume
|
68
|
||||
|
|
|
||||
|
- Price
|
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
9 September 2025
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Tamara Rogers
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Marketing Officer - PDMR
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification code
|
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares
under the Company's Share Reward Plan
|
|||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.6182
|
34
|
|
|
|
|
|
£Nil
|
34 (Matching Shares)
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
|
|
||||
|
- Aggregated volume
|
68
|
||||
|
|
|
||||
|
- Price
|
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
9 September 2025
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
September 10, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
FAQ
What PDMR transaction did Haleon (HLN) disclose on 10 September 2025?
Does the Form 6-K identify the individual PDMR who traded HLN shares?
Is this Haleon disclosure a routine regulatory filing?
Where can I find more information about Haleon’s business and brands?
Does the filing include financial results or material corporate actions?
